Is Biostack profitable in 2026?

No revenue figures are disclosed. Biostack is a seed-stage startup founded around October 2025 that claims (its own words) '17 customers and prospects including top AI labs' as of its May 25, 2026 YC launch, but this traction is unverified with no named logos or contract values.

Who are Biostack's biggest competitors?

Biostack faces generalist data-infra giants Mercor (~$10B valuation, Oct 2025), Handshake ($1B+ ARR, Apr 2026), Scale AI (~$14B Meta stake, 2025), and Surge AI, plus healthcare-RWD incumbents Truveta ($320M Series C, 2025) and Datavant, all already positioned in its niche.

Could AI or larger platforms replace Biostack?

Yes, this is a live risk. Biostack's core work, converting clinical records into ML-ready datasets and RL environments, is the exact task Mercor, Surge, Handshake, and Scale are bundling into existing frontier-lab relationships, per July 2026 industry reporting.

Who owns or funds Biostack?

Biostack is privately held and backed by Y Combinator (batch P26), with job postings (Mar 2026, company's own claim) listing investors as Afore Capital, Verdict Capital, Heroic Ventures, and angels from Meta and Google DeepMind. A third-party listing shows a $500,000 seed round dated June 1, 2026.

How much funding has Biostack raised?

A Caplight listing dated May 31, 2026 shows a Seed round dated June 1, 2026 totaling $500,000, though the listing's valuation and round detail fields are incomplete, making this figure low-confidence.

What is Biostack's biggest risk right now?

Its claimed edge, exclusive HIPAA-cleared clinical data access, is entirely unverified with no named agreements, while healthcare-data incumbents Truveta and Datavant already hold the hospital relationships Biostack would need to build from scratch.

YC Spring 2026 · United States

Biostack

getbiostack.com ↗

Sells healthcare data and RL training environments to AI labs, founded 2025.

Losing its protection

Assessed 27 July 2026 · Evidence as of 27 July 2026

The structural protection is eroding.

On the recordSince 27 July 2026 · Checkable from by late 2027 · Every call on the record Checkpoint: Window to sign named, exclusive multi-year health system or CRO data agreements

The call

Biostack sits in a hot market with two pivots behind it and no named exclusive data deal yet, while bigger, funded rivals already sell into the same AI labs.

Biostack sells clinical data and AI training environments to companies building artificial intelligence systems. The company claims it has exclusive access to hospital patient records that are approved for this use, but this claim has not been proven and the company has not yet built it. Biostack faces two big rivals: companies like Truveta and Datavant that already own relationships with hospitals and can sell data to AI labs, and larger data companies like Mercor and Scale that already work with AI labs and are now adding healthcare data to what they offer. The one thing that could save Biostack is if it signs long-term, exclusive deals with hospitals or research organizations in the next year that give it real advantages competitors cannot easily copy.

Why

AI pressure: AI labs building in-house synthetic and human-data pipelines. If frontier labs keep building their own health data and RL pipelines in-house, they never need to buy from Biostack at all. Could AI do the core job? Yes, likely.

Bigger players: Mercor, Handshake, Scale AI, Truveta, Datavant. Mercor, Handshake and Scale already sell data plus labor to the same AI labs, and Truveta and Datavant already hold the hospital data relationships Biostack needs. Could a giant copy it? Yes, easily.

What protects it. None confirmed yet: the claimed edge is exclusive hospital data access, but no signed exclusive agreement has been named or verified.

What would change this call

Biostack announces exclusive multi-year data deal with a named health system or CRO within 12-18 months. Would show its claimed regulated-data moat is real and defensible, not just planned.
Mercor, Surge, or Handshake launches a healthcare-vertical or clinical-RL product line. Would show incumbents are commoditizing Biostack's niche before it can lock in supply.
Biostack announces a third major pivot within 6 months of its May 2026 launch. Would show the team is still searching for a product, not building one.

Key numbers

Mercor valued at ~$10B (Oct 2025)
Handshake AI unit crossed $1B ARR (Apr 2026)
Biostack claims 17 customers and prospects (unverified) (May 2026)

Named risks

Two product pivots in under a year signal unstable product-market fit. Severity: high
Core '17 customers and prospects' claim is unverified with no named AI-lab logos. Severity: high
Incumbents Truveta and Datavant already hold the hospital data relationships needed. Severity: high
Mercor, Scale, Handshake, Surge bundling healthcare verticals into existing lab accounts. Severity: medium
Claimed HIPAA-cleared exclusive clinical data access has no verified named agreements. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Mercor	losing to	Reached ~$10B valuation Oct 2025, acquired Deeptune Jul 2026, bundling RL environments+labor into existing lab accounts
Truveta	losing to	Raised $320M Series C 2025, launched Genome Project with Regeneron/Illumina/Microsoft, already owns hospital data ties
Datavant	losing to	Reported ~$7B valuation (2025), already holds health-system data-sharing agreements Biostack lacks
Handshake	gaining on	AI unit ARR crossed $1B in Apr 2026, up from $550M in Jan 2026, expanding into vertical data
Scale AI	contesting	Took ~$14B Meta stake in 2025, reportedly lost some clients but remains dominant generalist data vendor

Questions people ask

Is Biostack profitable in 2026?: No revenue figures are disclosed. Biostack is a seed-stage startup founded around October 2025 that claims (its own words) '17 customers and prospects including top AI labs' as of its May 25, 2026 YC launch, but this traction is unverified with no named logos or contract values.
Who are Biostack's biggest competitors?: Biostack faces generalist data-infra giants Mercor (~$10B valuation, Oct 2025), Handshake ($1B+ ARR, Apr 2026), Scale AI (~$14B Meta stake, 2025), and Surge AI, plus healthcare-RWD incumbents Truveta ($320M Series C, 2025) and Datavant, all already positioned in its niche.
Could AI or larger platforms replace Biostack?: Yes, this is a live risk. Biostack's core work, converting clinical records into ML-ready datasets and RL environments, is the exact task Mercor, Surge, Handshake, and Scale are bundling into existing frontier-lab relationships, per July 2026 industry reporting.
Who owns or funds Biostack?: Biostack is privately held and backed by Y Combinator (batch P26), with job postings (Mar 2026, company's own claim) listing investors as Afore Capital, Verdict Capital, Heroic Ventures, and angels from Meta and Google DeepMind. A third-party listing shows a $500,000 seed round dated June 1, 2026.
How much funding has Biostack raised?: A Caplight listing dated May 31, 2026 shows a Seed round dated June 1, 2026 totaling $500,000, though the listing's valuation and round detail fields are incomplete, making this figure low-confidence.
What is Biostack's biggest risk right now?: Its claimed edge, exclusive HIPAA-cleared clinical data access, is entirely unverified with no named agreements, while healthcare-data incumbents Truveta and Datavant already hold the hospital relationships Biostack would need to build from scratch.

Timeline

2026-07-13YC directory snapshot shows Biostack headcount unclear, still actively hiring
2026-07-11Mercor acquires AI-simulation startup Deeptune, deepening bundled environments+labor threat
2026-06-01Seed round dated, $500K raised per Caplight listing (low confidence)
2026-05-25YC Launch: Biostack claims 17 customers/prospects, pivots to full post-training loop
2026-05-01Posts Founding Research Engineer, RL/Reasoning role
2026-03-28Clinical Data Lead job post names investors: YC, Afore, Verdict, Heroic Ventures
2025-12Abandons first pivot, multi-agent systems for biology, after about 2 months
2025-10Biostack founded, initially building multi-agent systems for biology research

Revision history

27 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Trellis Surtr Defense Systems HeyClicky